Trial Profile
A Phase III Trial of XELOX (Xeloda/Oxaliplatin) Followed by Xeloda Maintenance Versus Best Supportive Care (BSC) in Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 May 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 25 Apr 2017 Status changed from recruiting to discontinued.
- 11 Mar 2014 New trial record